Bleeding Events with Antithrombotic Therapy in Patients with Unstable Angina or non-ST-segment Elevation Myocardial Infarction; Insights from a Large Clinical Practice Registry (GRACE)

Heart Lung and Circulation

Volumn 17, Issue 1, 2008, Pages 5-8

  Stiles, Martin K ^a   Dabbous, Omar H ^b   Fox, Keith A A ^c  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Acute coronary syndromes; Bleeding; Heparin; Registry; Revascularisation; Thienopyridines

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; THIENOPYRIDINE DERIVATIVE;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DISEASE REGISTRY; GLOBAL REGISTRY OF ACUTE CORONARY EVENTS; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; ST SEGMENT ELEVATION; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; ELECTROCARDIOGRAPHY; FEMALE; HEMORRHAGE; HOSPITAL MORTALITY; HUMANS; INTERNATIONAL COOPERATION; MALE; MULTICENTER STUDIES AS TOPIC; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; PYRIDINES; REGISTRIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; THROMBOEMBOLISM;

EID: 37049032889     PISSN: 14439506     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hlc.2007.02.096     Document Type: Article

References (11)

1. Clopidogrel in unstable angina to prevent recurrent events (CURE) trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502.
2. Steinhubl S.R., Berger P.B., Tift Mann J., Fry E.T.A., DeLago A., Wilmer C., Topol E.J., and for the CREDO investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention trial. JAMA 288 (2002) 2411-2420
3. Leon M.B., Baim D.S., Popma J.J., Gordon P.C., Cutlip D.E., Ho K.K.L., Giambartolomei A., Diver D.J., Lasorda D.M., Williams D.O., Pocock S.J., and Kuntz R.E. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 339 (1998) 1665-1671
4. Mehta S.R., Yusuf S., Peters R.J.G., Bertrand M.E., Lewis B.S., Natajaran M.K., Malmberg K., Rupprecht H.J., Zhao F., Chrolavicius S., Copland I., and Fox K.A.A. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
5. The GRACE investigators. GRACE (Global Registry of Acute Coronary Events): a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 141 (2001) 190-199
6. Fox K.A.A. An introduction to the Global Registry of Acute Coronary Events: GRACE. Eur Heart J 2 Suppl. F (2000) F21-F24
7. Yusuf S., Mehta S.R., Zhao F., Gersh B.J., Commerford P.J., Blumenthal M., Budaj A., Wittlinger T., Fox K.A.A., and on behalf of the CURE trial investigators. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 107 (2003) 966-972
8. Bhatt D.L., Fox K.A., Hacke W., Berger P.B., Black H.R., Boden W.E., Cacoub P., Cohen E.A., Creager M.A., Easton J.D., Flather M.D., Haffner S.M., Hamm C.W., Hankey G.J., Johnston S.C., Mak K.H., Mas J.L., Montalescot G., Pearson T.A., Steg P.G., Steinhubl S.R., Weber M.A., Brennan D.M., Fabry-Ribaudo L., Booth J., Topol E.J., and for the CHARISMA investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
9. Lewis B.S., Mehta S.R., Fox K.A.A., Halon D.A., Zhao F., Peters R.J.G., Keltai M., Budaj A., Yusuf S., and for the CURE trial investigators. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results form the clopidogrel in unstable angina to prevent recurrent events (CURE) study. Am Heart J 150 (2005) 1177-1184
10. Hongo R.H., Ley J., Dick S.E., and Yee R.R. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 40 (2002) 231-237
11. Fox K.A.A., Mehta S.R., Peters R., Zhao F., Lakkis N., Gersh B.J., and Yusuf S. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome. The clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) trial. Circulation 110 (2004) 1202-1208